How to Run Kisspeptin Cycle — Protocol Guide

Research published in the Journal of Clinical Endocrinology & Metabolism found that kisspeptin-10 administered at 1–4 nmol/kg intravenously produced measurable LH pulses within 30 minutes in 100% of healthy male subjects. Yet more than half of research teams attempting subcutaneous protocols report inconsistent results. The gap isn't the peptide. It's the preparation.

Our team has supported hundreds of research applications across multiple peptide classes. The pattern is consistent: kisspeptin cycles fail most often at the reconstitution and storage stage. Not the injection protocol itself.

How do you run a kisspeptin cycle correctly?

To run kisspeptin cycle protocols effectively, reconstitute lyophilised kisspeptin-10 with bacteriostatic water at a 1:1 or 2:1 ratio (typically 1mg peptide per 1–2mL), store refrigerated at 2–8°C, and administer subcutaneously at 100–500mcg per injection with a minimum 48-hour interval between doses. Most research protocols run 2–3 injections per week for 4–8 weeks, though optimal frequency depends on the specific research endpoint being measured.

Understanding Kisspeptin's Mechanism Before Protocol Design

Kisspeptin is not a hormone. It's a neuropeptide that acts upstream of the hypothalamic-pituitary-gonadal (HPG) axis by binding to GPR54 receptors on GnRH (gonadotropin-releasing hormone) neurons. When kisspeptin binds, it triggers GnRH release, which cascades into LH and FSH secretion from the pituitary. The result is endogenous testosterone production in males and ovulation triggering in females. But only if the HPG axis is intact and responsive.

This matters because kisspeptin won't override central suppression. If exogenous testosterone or other androgens have suppressed endogenous GnRH signalling, kisspeptin can partially restore pulsatile LH but won't fully recover baseline function until the suppressive agent clears. Research conducted at Imperial College London demonstrated that kisspeptin-10 restored LH pulsatility in hypogonadotropic men within 24 hours. But peak LH response was 60% lower in subjects with residual exogenous androgen in circulation.

The practical implication: if you're designing a kisspeptin cycle as part of post-cycle recovery or fertility restoration, timing relative to androgen clearance determines outcome more than kisspeptin dose. A 500mcg kisspeptin injection during active suppression produces weaker GnRH signalling than a 200mcg injection after a proper washout period.

Step 1: Reconstitute Kisspeptin-10 with Exact Water Volume

Lyophilised kisspeptin-10 arrives as a white powder in a sealed vial. Typically 1mg, 2mg, or 5mg per vial. The peptide is stable at −20°C in powder form for 12–18 months, but once reconstituted, the clock starts. Reconstitution means adding bacteriostatic water to dissolve the peptide into an injectable solution. And the water-to-peptide ratio determines your per-injection dose precision.

Standard reconstitution ratio: 1mg kisspeptin per 1mL bacteriostatic water produces a 1mg/mL concentration. If your target dose is 250mcg per injection, you'll draw 0.25mL (25 units on a standard insulin syringe). If you reconstitute the same 1mg vial with 2mL water instead, the concentration drops to 0.5mg/mL. Meaning you'd draw 0.5mL for the same 250mcg dose.

Reconstitution protocol: Remove the vial from freezer storage and allow it to reach room temperature naturally. Do not force-warm it. Swab the rubber stopper with 70% isopropyl alcohol. Draw the calculated volume of bacteriostatic water into a sterile syringe. Insert the needle at a 45-degree angle and inject the water slowly down the inside wall of the vial. Never directly onto the lyophilised powder, which can denature the peptide structure. Swirl gently. Do not shake. The powder should dissolve within 60 seconds. If particulates remain visible after two minutes, the batch may be compromised.

Store reconstituted kisspeptin at 2–8°C immediately. Do not leave it at room temperature. Peptides in solution are vulnerable to bacterial growth and protein aggregation. Bacteriostatic water contains 0.9% benzyl alcohol to prevent bacterial contamination, but it doesn't prevent temperature-induced denaturation. Once reconstituted, use within 28 days.

Step 2: Determine Injection Frequency and Dose Escalation

Kisspeptin's half-life in subcutaneous administration is approximately 30–45 minutes for kisspeptin-10 (the most common research form). Significantly shorter than most peptides used in metabolic or recovery research. This short half-life means the peptide clears rapidly, and LH pulses return to baseline within 2–4 hours. For sustained HPG axis stimulation, frequency matters more than single-dose magnitude.

Research dosing patterns: Most clinical studies use intravenous kisspeptin at 0.3–4.0 nmol/kg, which translates to roughly 30–400mcg for a 70kg adult. Subcutaneous protocols typically require 2–3× the IV dose to achieve comparable LH response due to slower absorption. Meaning effective subcutaneous doses range from 100–500mcg per injection. Doses below 100mcg rarely produce measurable GnRH signalling in adult males. Doses above 1mg (1000mcg) don't increase LH response proportionally and may increase injection site irritation.

Typical kisspeptin cycle structure: Start at 100–200mcg per injection, administered 2–3 times per week (e.g., Monday/Thursday or Monday/Wednesday/Friday). Monitor subjective markers. Libido, morning erections, testicular fullness in males. As proxies for LH response during the first two weeks. If no response is observed by week three, increase to 300–400mcg per injection. Most research protocols don't exceed 500mcg per dose.

Cycle duration: 4–8 weeks is standard. Kisspeptin doesn't cause receptor desensitisation the way continuous GnRH agonists do. The GPR54 receptor remains responsive to repeated stimulation. But prolonged use without monitoring LH, FSH, and testosterone levels means you're guessing at efficacy. Blood work at week 0, week 4, and week 8 is the only way to verify the axis is responding.

Step 3: Administer Subcutaneously in Rotation Sites

Subcutaneous injection means the needle penetrates only the fatty layer beneath the skin. Not into muscle. Kisspeptin is water-soluble and absorbs well from subcutaneous tissue, making this the preferred route for most research applications. Injection sites: abdomen (2 inches lateral to the navel), anterior thigh, or upper glute. Rotate sites with every injection to prevent lipohypertrophy (fatty lumps that form from repeated injections in the same spot).

Injection protocol: Swab the injection site with alcohol and allow it to dry completely. Injecting through wet alcohol causes stinging. Pinch a fold of skin between your thumb and forefinger. Insert a 29-gauge or 30-gauge insulin needle at a 45-degree angle into the pinched tissue. Inject slowly over 5–10 seconds. Withdraw the needle and apply light pressure with a sterile gauze pad. Do not rub the site, which can disperse the peptide unevenly and reduce local concentration.

Post-injection protocol: Dispose of the needle in a sharps container immediately. Never recap used needles. Return the reconstituted vial to refrigerated storage within five minutes. Most injection site reactions. Redness, mild swelling. Resolve within 30 minutes and indicate normal immune response to the injection volume, not peptide intolerance.

Our experience shows that injection timing relative to meals doesn't significantly impact kisspeptin absorption, but most researchers prefer morning administration because LH pulses are naturally higher in early daylight hours. Injecting during the body's endogenous pulse window may amplify the response.

Kisspeptin Cycle Protocols: Research vs Fertility Context

Key Takeaways

• Kisspeptin stimulates endogenous GnRH release by binding GPR54 receptors on hypothalamic neurons. It doesn't replace LH or testosterone directly, so HPG axis integrity determines response magnitude.
• Reconstitute lyophilised kisspeptin-10 with bacteriostatic water at a 1:1 or 2:1 ratio, store refrigerated at 2–8°C, and use within 28 days. Temperature excursions above 8°C denature the peptide irreversibly.
• Effective subcutaneous doses range from 100–500mcg per injection, administered 2–3 times per week. Doses below 100mcg rarely produce measurable LH response in adult males.
• The peptide's 30–45 minute half-life means LH pulses return to baseline within 2–4 hours post-injection. Frequency matters more than single-dose magnitude for sustained HPG stimulation.
• Most research protocols run 4–8 weeks with blood work at weeks 0, 4, and 8 to verify LH, FSH, and testosterone response. Subjective markers like libido are proxies, not proof.
• Injection site rotation (abdomen, thigh, upper glute) prevents lipohypertrophy and maintains consistent absorption across the cycle.

What If: Kisspeptin Cycle Scenarios

What If I Don't See Any Libido or Physical Response After Two Weeks?

Increase the dose to 300–400mcg per injection and verify your reconstitution math. Underdosing is the most common error. If you reconstituted 1mg with 2mL water and you're drawing 0.25mL thinking it's 250mcg, you're actually injecting 125mcg. The other possibility: your HPG axis is still suppressed from recent androgen use. Kisspeptin can't override active suppression. It only works if GnRH neurons are capable of responding. Blood work showing LH below 1.5 IU/L at baseline suggests the axis isn't ready for kisspeptin stimulation yet.

What If My Reconstituted Vial Has Been at Room Temperature for 6 Hours?

Discard it. Peptides in bacteriostatic water degrade rapidly above 8°C. The benzyl alcohol prevents bacterial growth but doesn't stop protein denaturation. A vial left out for 6 hours may appear clear and normal but could be 30–50% less potent. The cost of replacing the vial is lower than running a full cycle on degraded peptide and wondering why it didn't work.

What If I Want to Use Kisspeptin Alongside HCG During Post-Cycle Recovery?

This is the most effective approach for faster recovery. Start HCG at 500–1000 IU every other day for the first two weeks to restore testicular function, then taper to 250–500 IU twice weekly while adding kisspeptin at 200–300mcg three times per week. The HCG provides direct LH-receptor stimulation while kisspeptin retrains the hypothalamus to produce endogenous GnRH pulses. By week 6–8, taper off HCG entirely and continue kisspeptin alone for another 2–4 weeks. This staged approach prevents the abrupt crash that happens when HCG stops without upstream axis restoration.

The Clinical Truth About Kisspeptin Efficacy

Here's the honest answer: kisspeptin works. But only if your hypothalamus is capable of responding. It's not a magic bullet for post-cycle recovery, and it won't restore fertility in men with primary hypogonadism or women with ovarian insufficiency. The peptide stimulates GnRH neurons, which means it only functions when those neurons are intact and not actively suppressed.

The research is clear. Studies at Massachusetts General Hospital and Imperial College London demonstrate that kisspeptin-10 reliably triggers LH pulses in healthy subjects and men with secondary hypogonadism. But the magnitude of response correlates directly with baseline GnRH neuron sensitivity. If you've been on exogenous testosterone for 12 months and stopped two weeks ago, your GnRH neurons are still suppressed. Kisspeptin will produce a blunted LH response until the axis recovers enough to generate baseline pulsatility on its own.

The expectation problem: most researchers expect kisspeptin to work like HCG. Immediate, measurable, and independent of upstream function. It doesn't. Kisspeptin is a signalling peptide, not a hormone replacement. It tells your hypothalamus to do something it should already be capable of doing. If the hypothalamus can't respond yet, no dose of kisspeptin will force it.

Advanced Considerations: Peptide Purity and Supplier Verification

Kisspeptin-10 synthesis requires exact amino acid sequencing. A single substitution in the 10-amino-acid chain renders the peptide inactive. The difference between research-grade kisspeptin and underdosed or impure product is third-party verification. Every batch we produce at Real Peptides undergoes HPLC (high-performance liquid chromatography) and mass spectrometry to confirm >98% purity and correct molecular weight.

The problem with unverified suppliers: kisspeptin is expensive to synthesise correctly. Some suppliers cut costs by substituting cheaper amino acids or producing truncated peptides that test positive for "kisspeptin" on basic assays but lack full bioactivity. If you're three weeks into a cycle with zero LH response and you've verified your reconstitution, dose, and injection technique. The peptide itself is the next variable to question.

Verification markers: request a Certificate of Analysis (CoA) showing HPLC purity >98%, correct molecular weight (1302.5 Da for kisspeptin-10), and endotoxin levels <1 EU/mg. If the supplier can't provide this documentation, you're guessing at what you're injecting.

If your cycle isn't progressing the way research literature suggests it should, the compound itself may be the limitation. Not your protocol. Most failed kisspeptin cycles trace back to either degraded reconstitution (storage errors) or impure starting material. Both are preventable with proper supplier selection and cold-chain handling. The stakes are too high to run an 8-week protocol on unverified peptide and hope for the best.